Piramal Pharma has informed that as per the information received by the Company on March 20, 2026, SES ESG Research (‘SES ESG’), has assigned an Environment, Social and Governance (‘ESG’) Rating of ‘68.5’ for the Company for FY 2024-25 based on data made available by the Company in public domain for that year. The link for the rating as published is also available on the website. The Company has not engaged SES ESG for ESG Rating. SES ESG has voluntarily prepared the report considering the ESG factors reported by the Company. This intimation is also being uploaded on the website of the Company at https://www.piramalpharma.com/.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: